Scientific Release_Frontera Therapeutics, Inc.

Scientific Release

Year: All 2024

Safety and Efficacy of a Novel Gene Therapy Drug (FT-001) for the Treatment of RPE65 Biallelic Variation-associated Retinal Degeneration

2024 ARVO

Ruifang SUI|2024-05
Preliminary Safety and Efficacy Results from a Pilot Gene Therapy Study of FT-002 in Subjects with RPGR Gene Mutation associated X-linked Retinitis Pigmentosa (XLRP)

27th ASGCT

Ruyi HAN|2024-05
Efficacy and Safety of a Novel RPGROFR15 Gene Therapy (FT-002) for the Treatment of RPGR-Associated XLRP

27th ASGCT

Zhong-Dong SHI|2024-05
Development of an AAV Gene Therapy Vector FT-004 for Hemophilia B

27th ASGCT

Zhong-Dong SHI|2024-05
Developing an AAV-based Gene Therapy for MYBPC3 Mutation-Associated Hypertrophic Cardiomyopathy

27th ASGCT

Therese S. Salameh |2024-05
AAV KP1 Efficiently Transduces Human Cell Lines in vitro and Mouse Liver but not Non-Human Primate Liver after Intravenous Injection

27th ASGCT

Zhong-Dong SHI|2024-05

1 2

Together with Us
To Build Health and the Future

Contact Us

Boston R&D Center：+1 617-5467300Shanghai Operation Center：+86 21-58206061Suzhou Manufacturing Site：+86 512-85883110

Legal Notice Copyright © 2025 Frontera Therapeutics, Inc. 沪公网安备31011502401398号 Powered by Xinhongru